Cite
HARVARD Citation
Kavanaugh, A. et al. (2014). OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. Annals of the rheumatic diseases. pp. 90-91. [Online].